10q10k10q10k.net
Moderna

ModernaMRNAEarnings & Financial Report

Nasdaq · Health Care · Biotechnology

Moderna, Inc. is an American pharmaceutical and biotechnology company based in Cambridge, Massachusetts, that focuses on RNA therapeutics, primarily mRNA vaccines. These vaccines use a copy of a molecule called messenger RNA (mRNA) to carry instructions for proteins to produce an immune response. The company's name is derived from the terms "modified", "RNA", and "modern".

NextFeb 21, 2026

MRNA Q3 2025 Key Financial Metrics

売上高

$1.0B

粗利益

$809.0M

営業利益

$-260.0M

純利益

$-200.0M

粗利益率

79.6%

営業利益率

-25.6%

純利益率

-19.7%

前年比成長

-45.4%

EPS

$-0.51

来期コンセンサス
EPS$-2.10-311.8%

資金フロー

Moderna Q3 2025 Financial Summary

Moderna reported revenue of $1.0B for Q3 2025, with a net profit of $-200.0M (-19.7% margin). Cost of goods sold was $207.0M, operating expenses totaled $1.1B.

Key Financial Metrics

Total Revenue$1.0B
Net Profit$-200.0M
Gross Margin79.6%
Operating Margin-25.6%
Report PeriodQ3 2025

Moderna Annual Revenue by Year

Moderna annual revenue history includes year-by-year totals (for example, 2024 revenue was $3.2B).

YearAnnual Revenue
2024$3.2B
2023$6.8B
2022$19.3B

損益計算書

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
売上高$2.81B$167.0M$241.0M$1.86B$966.0M$108.0M$142.0M$1.02B
前年比成長-44.7%-91.0%-29.9%1.7%-65.6%-35.3%-41.1%-45.4%

貸借対照表

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
総資産$18.43B$16.73B$15.68B$15.80B$14.14B$12.70B$12.01B$12.13B
総負債$4.57B$3.91B$3.97B$3.88B$3.24B$2.64B$2.61B$2.81B
株主資本$13.85B$12.82B$11.71B$11.93B$10.90B$10.07B$9.40B$9.33B

キャッシュフロー

Q4 2023Q1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025
営業CF$622.0M$-989.0M$-1.27B$-1.57B$825.0M$-1.04B$-919.0M$-847.0M